Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine - PubMed
Affiliations
- PMID: 17277725
Clinical Trial
Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine
Gerhard Waberzinek et al. Neuro Endocrinol Lett. 2007 Feb.
Abstract
This multicenter study investigated the safety and efficacy of intravenous valproate in acute migraine attacks and the possible impact of prophylactic valproate pre-treatment. Thirty-six patients established on migraine prophylaxis were administered 500 mg sodium valproate intravenously against acute migraine attacks. Pain development was assessed by visual analogue scale up to a 24 hours follow up interview to detect e.g. possible relapse symptoms. A subgroup analysis examined whether prophylactic treatment with valproate affected its acute anti-migraine efficacy. A meaningful headache reduction within two hours was achieved in all 12 patients with and in 20 out of 24 patients without valproate prophylaxis. Headache-associated signs and symptoms were substantially reduced. No serious side-effects were reported. The results confirm the therapeutic value of intravenous valproate in acute migraine attacks described in literature and show a beneficial effect on all investigated efficacy parameters with a trend to even better response in patients receiving valproate prophylaxis.
Similar articles
-
Tanen DA, Miller S, French T, Riffenburgh RH. Tanen DA, et al. Ann Emerg Med. 2003 Jun;41(6):847-53. doi: 10.1067/mem.2003.195. Ann Emerg Med. 2003. PMID: 12764341 Clinical Trial.
-
Valproate versus flunarizine in migraine prophylaxis: a randomized, double-open, clinical trial.
Mitsikostas DD, Polychronidis I. Mitsikostas DD, et al. Funct Neurol. 1997 Sep-Oct;12(5):267-76. Funct Neurol. 1997. PMID: 9439944 Clinical Trial.
-
Treatment of primary headache disorders with intravenous valproate: initial outpatient experience.
Stillman MJ, Zajac D, Rybicki LA. Stillman MJ, et al. Headache. 2004 Jan;44(1):65-9. doi: 10.1111/j.1526-4610.2004.04010.x. Headache. 2004. PMID: 14979885 Clinical Trial.
-
Divalproex in the treatment of migraine.
Freitag FG. Freitag FG. Psychopharmacol Bull. 2003;37 Suppl 2:98-115. Psychopharmacol Bull. 2003. PMID: 15021865 Review.
-
Valproate semisodium ER for migraine and cluster headache prophylaxis.
Lovell BV, Marmura MJ. Lovell BV, et al. Expert Opin Drug Metab Toxicol. 2010 Apr;6(4):495-504. doi: 10.1517/17425251003693547. Expert Opin Drug Metab Toxicol. 2010. PMID: 20298131 Review.
Cited by
-
Mazaheri S, Poorolajal J, Hosseinzadeh A, Fazlian MM. Mazaheri S, et al. PLoS One. 2015 Mar 20;10(3):e0120229. doi: 10.1371/journal.pone.0120229. eCollection 2015. PLoS One. 2015. PMID: 25793707 Free PMC article. Clinical Trial.
-
Karimi N, Tavakoli M, Charati JY, Shamsizade M. Karimi N, et al. Clin Exp Emerg Med. 2017 Sep 30;4(3):138-145. doi: 10.15441/ceem.16.199. eCollection 2017 Sep. Clin Exp Emerg Med. 2017. PMID: 29026887 Free PMC article.
-
The pharmacological management of migraine, part 1: overview and abortive therapy.
Demaagd G. Demaagd G. P T. 2008 Jul;33(7):404-16. P T. 2008. PMID: 19750119 Free PMC article.
-
Advances in drug development for acute migraine.
Cady RJ, Shade CL, Cady RK. Cady RJ, et al. Drugs. 2012 Dec 3;72(17):2187-205. doi: 10.2165/11641120-000000000-00000. Drugs. 2012. PMID: 23116251
-
Valproate in conversion disorder: a case report.
Messina A, Fogliani AM. Messina A, et al. Case Rep Med. 2010;2010:205702. doi: 10.1155/2010/205702. Epub 2010 Jun 30. Case Rep Med. 2010. PMID: 20671980 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical